Cite
HARVARD Citation
An, I. et al. (2020). A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide. Diabetes, obesity & metabolism. 22 (8), pp. 1455-1468. [Online].